Actively Recruiting
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-01-08
115
Participants Needed
1
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3276 for injection in patients with advanced solid tumors.
CONDITIONS
Official Title
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to sign a written informed consent
- Age 18-70 years old (both male and female)
- Pathologically confirmed advanced malignant tumors with failed or no effective standard treatment
- Presence of measurable lesions
- ECOG performance status 0-1
- Expected survival of at least 12 weeks
- Major organs functioning within required limits
- Fertile females must have a negative serum pregnancy test within 7 days before first dose and must not be breastfeeding
You will not qualify if you...
- Symptomatic central nervous system or meningeal metastases
- Untreated spinal cord compression by surgery or radiotherapy
- Uncontrolled tumor-related pain
- Uncontrolled third space effusions (pleural, pericardial, or peritoneal)
- Systemic antitumor therapy within 28 days prior to first treatment
- Surgery requiring general anesthesia within 28 days prior to first treatment or planned during study
- Serious adverse reactions from prior immune checkpoint inhibitor therapy
- Unresolved toxicities from previous anticancer treatment above grade 1
- Use of live attenuated vaccines within 28 days before or during treatment
- Systemic immunosuppressive therapy within 14 days before first treatment
- Arterial or venous thrombosis within 3 months before first treatment
- Clinically significant lung disease
- History of autoimmune diseases
- Other malignancies within 5 years before treatment
- Known severe allergies to the investigational drug or its ingredients
- History of immune deficiency or organ transplantation
- Other serious illnesses that may compromise treatment safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of PLA Army Medical University
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
Research Team
Z
Zhenqun Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here